Precision AQ
Cherry Moldovan, PhDDirector
Cherry Moldovan is a Director, Strategic Consulting, at Precision AQ, where she advises pharmaceutical and biotechnology companies on commercial strategy and market access across therapeutic areas, including oncology, hematology, rare diseases, nephrology, autoimmune, respiratory, and cardiovascular conditions. Her experience spans the product lifecycle from clinical development through post-approval commercialization. She has supported initiatives including launch sequence optimization, pricing and market access strategy, value communication and messaging, payer and provider contracting, lifecycle and loss-of-exclusivity planning, innovative contracting models, and clinical advisory boards for strategic program planning.
Insights from Cherry Moldovan, PhD
Commercialization & Access | Industry Brief
Twenty-Five Years of Antibody–Drug Conjugates: From Breakthroughs to Access by Design
Commercialization & Access | White Paper
Challenges and Opportunities for Radiopharmaceutical Commercialization
Commercialization & Access | White Paper
China Market Access After NRDL Maturity: What Comes After the Price Reset?
NRDL inclusion is no longer the finish line. See why reimbursement alone doesn’t guarantee real-world utilization.